Viamet Pharmaceuticals

Viamet identifies and and develops small molecule inhibitors of key metalloenzymes via a proprietary medicinal chemistry platform, our Metallophile® Technology. The Metallophile Technology has allowed us to discover and develop a portfolio of proprietary antifungal compounds with the potential to address significant unmet medical needs.

We have assembled a world-class team that comprises expertise in computational and medicinal chemistry, drug discovery and clinical development. The team is complemented by scientific and clinical advisors with broad expertise in pharmaceutical development and clinical practice.